Novartis AG (NYSE:NVS) is highlighted as one of the most profitable healthcare stocks to buy, with strong momentum and sales growth guidance through 2030. The company expects to be protected from U.S. tariffs by mid-2026, as it invests in regional supply chains to minimize exposure to trade policies. Novartis AG, based in Switzerland, offers pharmaceutical products like Entresto and Cosentyx. Despite its potential, some believe other AI stocks offer greater upside potential. Jim Cramer is optimistic about Novartis’ (NVS) cancer drug, citing an agreement with the U.S. government that will exclude the company from tariffs.

Read more at Yahoo Finance: Why Analysts Are Closely Watching Novartis AG (NVS)